New therapies in non-Hodgkin lymphoma. - Wikidata - awgldk - TriplyDB

New therapies in non-Hodgkin lymphoma.

New therapies in non-Hodgkin lymphoma.

http://www.wikidata.org/entity/Q38315779

about

Allogeneic hematopoietic stem cell transplantation for non-Hodgkin's lymphomas: a retrospective analysis of 77 cases.

P2860

Q40342288-948949D0-4E92-4EDD-A6EA-C156D9F9703E

P2860

New therapies in non-Hodgkin lymphoma.

http://www.wikidata.org/entity/Q38315779

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

New therapies in non-Hodgkin lymphoma.

@en

type

label

New therapies in non-Hodgkin lymphoma.

@en

prefLabel

New therapies in non-Hodgkin lymphoma.

@en

P1433

Q38315779-78389420-F21D-45D5-8466-79569A2C3B84

P1476

Q38315779-3467C3BE-369D-47C8-B9F0-8D678BCFFAD5

P2093

Q38315779-AC459238-8F88-492A-A8F1-ACC7B468EEB5

P2860

Q38315779-00CBCC65-EEDC-463B-B9A4-D77BA86F2DFD

Q38315779-0105FE26-9192-464D-BF59-A346A77E1E6B

Q38315779-0455500E-34A1-4355-A814-24ECBF204EC2

Q38315779-06363E29-F8BB-4CEF-A9CB-386EA63A5D6B

Q38315779-07B4EBFD-7BAF-43F3-B158-7AF7708EA7AC

Q38315779-08E3C829-1A03-40C0-B2D9-42348D91B789

Q38315779-0E104148-1D10-4DA0-BCDD-719E0A3A6085

Q38315779-13343A9F-7BCA-488A-8F2C-126643B83B94

Q38315779-14B5DE29-9A67-4A4B-93BF-3698C66B1C6A

Q38315779-182A852C-A293-4566-946B-10F38BB54C71

P304

Q38315779-C7E2A34B-F15D-4F84-8D54-B01E51527737

P31

Q38315779-2CBEF85A-914C-4FE4-9FD3-2A0AED32B818

P356

Q38315779-95BD8A94-A236-46F6-8B9E-D04DF04EB6ED

P433

Q38315779-131518BA-E126-4563-A28C-7BD0841474FA

P478

Q38315779-879C0D23-6DD3-4FA9-BF29-E8E04A863050

P50

Q38315779-5CC8D706-BD39-479E-84AA-3FFC64E93392

Q38315779-8944D50A-1F47-493E-A7CE-D1A5032679EF

P577

Q38315779-9F3B2018-AEB8-4E44-BB4D-748D0BF37F36

P698

Q38315779-7F0F2222-9F34-421F-9664-FE9C9FD7447C

P356

14737140.2015.1002773

P1433

Expert Review of Anticancer Therapy

P1476

New therapies in non-Hodgkin lymphoma.

@en

P2093

Jorge Sierra

http://www.w3.org/2001/XMLSchema#string

P2860

A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma

Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma

B lymphocyte antigen receptor signaling: initiation, amplification, and regulation

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

NF-kappaB in cancer: from innocent bystander to major culprit

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia

Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study.

Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma

Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies.

A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma.

P304

349-359

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/14737140.2015.1002773

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P50

Silvana Novelli

P577

2015-01-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25582186

http://www.w3.org/2001/XMLSchema#string